Reviewer’s report

Title: Nature and Prevalence of Adverse drug reaction of Antiretroviral Medications in Halibet National Referral Hospital: a retrospective study.

Version: 0 Date: 12 Nov 2018

Reviewer: Narumol Jarernsiripornkul

Reviewer's report:

Specific comments
Thank you for the opportunity to review this manuscript. There are some comments that the authors need to address.
1. Abstract
   * Methods:
   * The study period is unclear. Please clarify the month in 2005.
   * Statistical tests should be mentioned.
   * Results: Please specify the common suspected drugs in relation to the common ADRs presented.
   * Conclusion: Suggestion on impact on findings at the last sentence is preferred, rather than the limitations.

2. Background
   * Please clarify more detail about the magnitude of problems regarding the international level.

3. Methods
   * I was wondering whether the study design was longitudinal study since it was only performed in 3 month-period. Was there any repeated data collection over time during the study period in 2005-2016?
   * Please clarify more detail about the selection of study samples. How to recruit 309 study samples from the total of 1242 patients? Was there any sampling method used?
   * How to identify the suspected drug from the combined drugs which are commonly prescribed in patients with HIV.
   * Again, please specify the starting month in 2005.
   * Statistical tests should be mentioned in data analysis.

4. Results
   * Page 7: percentages of male and female should be shown in the results. To make it clear, the common suspected drugs with the specific ADRs should be presented either in table or text.
   * The findings should be presented in order according to the objectives of study.
   * No causality assessment data classified by Naranjo's algorithm is found. All ADR categories should be shown as number and percentage.
   * Further detail of all evaluated factors need to address in the results. Presentation in table would
be beneficial.
*  Page 9, line 45-46: Specific treatment and symptomatic management are not clear since some of ADRs require both management.
*  Please specify or add percentages of patients or ADRs at the heading of Tables and axis of Figures.

5. Discussion
*  Please discuss more detail about the seriousness of ADRs in particular the lipodystrophy. I am uncertain how to assess the seriousness for some types of symptomatic ADRs.
*  Further discussion about the common suspected drugs and their related ADRs found in the current study is needed.
*  Page 10, line 56-60: It is not clear. Please clarify this sentence.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Unable to assess

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

No

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:
1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests' below.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal.